immunodiagnosticsystems

RatLaps™ EIA

Enzymeimmunoassay for the quantitative determination of fragments of type I collagen in rat/mouse serum or urine and released from rat/mouse bone into cell culture supernatants during bone resorption in vitro

For Research Use Only. Not for use in diagnostic procedures.

REF AC-06F1 Σ 96

INTRODUCTION

Intended use and type of procedure
RatLaps™ EIA is an enzyme-linked immunosorbent assay for the quantitative determination of bone-related degradation products from C-terminal telopeptides of type I collagen in rat/mouse serum or urine and from rat/mouse bone released into cell culture supernatants by osteoclasts. The assay is for research-use-only.

Summary and explanation of the test
Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesized primary in bone (1). During renewal of the skeleton bone matrix is degraded and consequently fragments of type I collagen is released into circulation. The resorption process can be studied *in vitro* by culturing bone cells on slices of bone or dentin.

The RatLaps™ EIA are based on the observation that certain C-telopeptide degradation products from type I collagen released during osteoclastic bone resorption. With RatLaps™ EIA it is possible to measure this degradation products in rat/mouse serum and urine and bone cell culture supernatants (2-8).

Principle of the procedure
The RatLaps™ EIA is based upon the competitive binding of a polyclonal antibody to soluble RatLaps antigens EKSQDGGR or to immobilized RatLaps antigens. Briefly, the polyclonal antibody is raised against a synthetic peptide having a sequence (EKSQDGGR) specific for a part of the C-terminal telopeptide α1 chain of rat type I collagen. For standardization of the RatLaps™ EIA a synthetic peptide (EKSQDGGR), which is specific for the C-terminal telopeptide α1 chain of type I collagen in rats has been used.

During the pre-incubation step, biotinylated EKSQDGGR is immobilized by binding to the streptavidin-coated microtitre wells. The wells are emptied and washed. Standards, control, or unknown samples (culture supernatant or rat/mouse serum or urine) are pipette into appropriate wells, followed by a solution of a primary antibody (polyclonal rabbit). Following the primary-incubation step the wells are emptied and washed. In the secondary-incubation step a solution of a Goat anti-Rabbit antibody conjugated with peroxidase (secondary antibody) is added and binds to the polyclonal rabbit antibody. After the third washing step a chromogenic substrate (TMB) is added and the color reaction is stopped with sulfuric acid. Finally, the absorbence at 450 nm is measured with 650 nm as reference if possible. The absorbence level is inversely related to concentration of RatLaps antigens in the sample.

PRECAUTIONS

Storage
Store the RatLaps™ EIA upon receipt at 2-8°C.
Under these conditions the reagents are stable until the expiry date stated on each vial.

Warnings
The RatLaps™ EIA is for research-use-only and is not for internal use in humans or animals. This product must be used strictly in accordance with the instructions set out in the Package Insert. IDS Limited will not be held responsible for any loss or damage (except as required by statute) howsoever caused, arising out of non-compliance with the instructions provided.
CAUTION: this kit contains material of animal origin. Handle kit reagents as if capable of transmitting an infectious agent.
Appropriate precautions and good laboratory practices must be used in the storage, handling and disposal of the kit reagents. Disposal of kit reagents should be in accordance with local regulations..
Do not use reagents beyond their expiration date and do not mix reagents from different lots of kits.

MATERIAL

Specimen collection
Please note that we strongly recommend using serum samples for investigation of *in vivo* models of

bone disease, since this will give the best results due to reduced variability. However, the procedure can also be utilized with urinary samples.

Important: *Samples should be collected as **fasting** samples.*

For rat/mouse it is advised to take fasting urine or serum sample after a minimum of 6 hours of fasting, e.g. in the after-noon.

SERUM: Rat/mouse serum samples should be collected as fasting samples. It is recommended to store rat serum samples at or below -20˚C. The samples are stable at –20ºC for 18 months.

URINE: Urinary samples can be collected as spot samples. Alternatively, urinary samples can also be collected as 24-hour urine samples by using metabolic cages or similar devices. It is recommended to store collected rat urine at 2-8˚C for no more than one week, but in general at or below -20˚C for prolonged storage. Results obtained by using urinary samples should be corrected for creatinine prior to evaluation.

CULTURE: Culture supernatants harvested from bone cells cultured on surfaces of bone or dentin from rat or mouse. Test culture supernatants the same day they are harvested or store at or below -20˚C for prolonged storage.

Materials supplied
Before opening the kit, please read the section on Precautions.
The kit contains reagents sufficient for 96 determinations.

Streptavidin coated microtitre plate **MICROPLAT**
Microwell strips (12 x 8 wells) pre coated with streptavidin. Supplied in a plastic frame.

RatLaps Standard **CAL** | **0**
One vial (min. 5.0 mL) of a ready-for-use TRIS-buffered solution with protein stabilizer and preservative.

RatLaps Standards **CAL** | **1** - **5**
Five vials (min. 0.4 mL/vial) ready-for-use, containing a synthetic peptide, EKSQDGGR, in a TRIS-buffered solution with protein stabilizer and preservative. Please refer to the vial label for the exact concentrations.

Control **CTRL**
One vial (min. 0.4 mL) ready-for-use, containing a synthetic peptide, EKSQDGGR, in a TRIS-buffered solution with protein stabilizer and preservative. Please refer to the enclosed QC Report for the control range.

Biotinylated RatLaps Antigen **Ag BIOTIN**
One vial (min. 12.0 mL) of a ready-for-use solution containing a biotinylated peptide, EKSQDGGR, in a PBS-buffered solution with protein stabilizer and preservative.

Primary Antibody **Ab**
One vial (min. 12.0 mL) of ready-for-use solution containing polyclonal antibody specific for a part of the C-telopeptide α1 chain of rat type I collagen, in a buffered solution with protein stabilizer and preservative.

Peroxidase Conjugated Goat anti-Rabbit IgG **ENZYMCONJ**
One vial (min. 12.0 mL) of ready-for-us solution of peroxidase conjugated Goat anti-Rabbit IgG antibody in a buffered solution with protein stabilizer and preservative.

Substrate Solution **SUBS** | **TMB**
One vial (min. 12.0 mL) of a ready-for-use tetramethylbenzidine (TMB) substrate in an acidic solution.

Stopping Solution **H2SO4**
One vial (min. 12.0 mL) of ready-for-use 0.18 M sulfuric acid.

Washing Solution **WASHBUF** | **50x**
One vial (min. 20.0 mL) of a concentrated Washing Solution containing detergent and preservative.

Sealing tape
Adhesive film for covering wells during incubation.

Materials required – not supplied
- Container for preparation of washing solution
- Precision micropipettes to deliver 20 µL
- Distilled or deionised water
- Precision 8 or 12-channel multipipette to deliver 100 µL
- ELISA plate reader with 450 nm, and 650 nm as reference wavelength
- 2 – 8˚C incubator

ASSAY PROCEDURE

Prior to use, equilibrate all solutions to room temperature (18-22°C). Mix all reagents and samples before use (avoid foam).

Determine the number of strips needed for the entire experiment. It is recommended to test all samples in duplicate. In addition, for each ELISA plate 14 wells are recommended for the standards and the Control.

Place the appropriate number of strips in the plastic frame. Store unused immunostrips in the tightly closed foil bag with desiccant capsules.

1. **Pre-incubation**
   Add 100 µL of Biotinylated RatLaps Antigen **Ag BIOTIN** to each well, cover with sealing tape, and incubate for 30±5 minutes at room temperature (18-22°C).

2. **Washing**
   Wash the immuno strips 5 times manually with 300 µL Washing Solution (**WASHBUF** **50x** diluted 1+50 in distilled or deionized water). Using an automated plate washer, follow the instructions of the manufacturer or the guidelines of the laboratory. Usually 5 washing cycles are adequate. Make sure that the wells are completely emptied after each manual or automated washing cycle.

3. **Primary incubation**
   Add 20 µL of Standards **CAL** **0** - **5**, Control **CTRL** or unknown samples into the appropriate wells followed by 100 µL of Primary Antibody **Ab**. Cover the immuno strips with sealing tape and incubate over night (18±3 hours) at 2-8°C.

4. **Washing**
   See step 2

5. **Secondary incubation**
   Add 100 µL of the Peroxidase conjugated Goat anti-Rabbit IgG Antibody **ENZYMCONJ** to each well, cover with sealing tape, and incubate for 60±5 minutes at room temperature (18-22°C).

6. **Washing**
   See step 2

7. **Incubation with chromogenic substrate solution**
   Pipette 100 µL of the Substrate Solution **SUBS** **TMB** into each well and incubate for 15±2 minutes at room temperatur in darkness. Use sealing tape

8. **Stopping of color reaction**
   Pipette 100 µL of the Stopping Solution **H2SO4** into each well.

9. **Measurement of absorbance**
   The absorbance is measured within two hours at 450 nm. It is recommended to use the reading at 650 nm as reference.

Limitations of the procedure
If the absorbance of a sample is lower than Standard 5, it is recommended that the sample is diluted 1+1 with Standard 0. It is not recommended to dilute a high sample more than 1+3.

QUALITY CONTROL

Good Laboratory Practice requires the use of quality control specimens in each series of assays in order to check the performance of the assay. Controls should be treated as unknown samples, and the results analyzed with appropriate statistical methods.

RESULTS

Calculation of results
Calculate the mean of the duplicate absorbance determinations. Construct a standard curve using 4-parametric logistic curve fit with mean absorbances of the six standards 0-5 (ordinate) against the corresponding RatLaps concentrations (abscissa). The RatLaps analyte concentration of the controls and each patient sample is determined by interpolation.

Example:

Standards/ Controls / Specimen	RatLaps conc. (ng/mL)	$A_{450-650}$ (nm)	Mean $A_{450-650}$ (nm)	Interpolated RatLaps conc. (ng/mL)
Standard 0	0	2.144/2.100	2.122	
Standard 1	7.7	1.566/1.622	1.594	
Standard 2	16.0	1.346/1.351	1.349	
Standard 3	44.3	0.914/0.922	0.918	
Standard 4	86.9	0.631/0.575	0.603	
Standard 5	188.1	0.361/0.355	0.358	
Control		0.748/0.703	0.726	67.4
Sample I		1.641/1.606	1.624	10.2
Sample II		0.845/0.962	0.904	55.2
Sample III		0.545/0.535	0.504	134.5

Please note: The data above are for illustration only and should not be used to calculate the results of any run.

Performance characteristics
Detection limit: 2.0 ng/mL

This is the concentration corresponding to two standard deviations below the mean of 21 determinations of RatLaps Standard 0.

Imprecision
The imprecision of RatLaps™ EIA was evaluated for three samples (low, medium, high)

Intra-assay variation
The number of determination of each sample was 21.

Sample	Mean level (ng/mL)	SD (ng/mL)	CV (%)
Low	13.0	1.2	9.2
Medium	49.8	2.8	5.6
High	143.0	8.3	5.8

Inter-assay variation
The inter-assay variation is based on 10 consecutive runs according to NCCLS EP5-A (2)

Sample	Mean level (ng/mL)	SD (ng/mL)	CV (%)
Low	13.5	2.0	14.8
Medium	65.0	6.8	10.5
High	140.1	15.0	10.7

Linearity
A rat serum sample was diluted with Standard 0 determined in the RatLaps™ EIA.
The result is summarized in the table below:

Dilution procedure		Expected	Observed	Recovery
Serum 60.7 ng/mL (parts)	Standard 0 0.0 ng/mL (parts)	(ng/mL)	(ng/mL)	(%)
1 1 1	1 3 7	30.4 15.2 7.6	34.8 17.5 8.7	114.5 115.1 114.5
Serum 49.6 ng/mL (parts)	Standard 0 0.0 ng/mL (parts)			
1 1 1	1 3 7	24.8 12.4 6.2	20.1 12.8 5.1	81.0 103.2 82.3

Expected values
Due to the age dependent bone turnover activity it is important to choose animals at appropriate age for the experimental set-up. In mice (strain C57bl/6J) the average urinary RatLaps level dropped from 110 ng/mL (age 4 weeks) to 18 ng/mL (age 10 weeks). At an age above 10 weeks the RatLaps value was quite stable. In rats (strain Lewis) the RatLaps levels decreased from 5 ng/mL (13 weeks) to 2 ng/mL (17 weeks).

EXPERIMENT EXAMPLE

Three-month-old female rats (Sprague-Dawley) were randomly allocated into three groups:
(1) Sham operation (n=10), (2) ovariectomy (OVX) (n=10), and (3) ovariectomy and subsequent subcutaneous placement of slow release 17b-estradiol pellets (0.5 mg, corresponding to 8 mg/day) (OVE+EE) (n=10).

All serum samples were collected after 6 hours of fasting (no food and water). Start of fasting was at 7.00 in the morning, and samples were collected after 13.00.

The first blood samples were collected on day 0 before the operation. Serum samples were tested in RatLaps™ EIA for fragments of the type I collagen (CTX) and in Rat-MID™ Osteocalcin EIA for the mid-molecular part (amino acid 21-29) of osteocalcin. All measurements were expressed in % of baseline measurement, for each individual rat. The error bars on the figure above are SEM.

The RatLaps™ EIA rapidly detects the increase in bone resorption following ovariectomy. Within two weeks after surgery RatLaps increases to 186% of pre-operation levels. This increase in bone resorption could be completely inhibited with estradiol. Similarly, Rat-MID™ Osteocalcin EIA detects the increase in bone formation induced by ovariectomy. Within two weeks after surgery Rat-MID increases to 146 % of pre-operation levels. Also this increase could be completely inhibited with estradiol.
Conclusion: Serum measurement of RatLaps™ EIA and Rat-MID™ Osteocalcin EIA detects the change in bone resorption and bone formation that is induced by ovariectomy of the rat.





REFERENCES

1. Burgeson RE. New collagens, new concepts. *Annu Rev Cell Biol (1988)4:552-77.*
2. Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline. *NCCLS EP5-A Vol.19, No.2, February 1999*
3. Garnero P. et al., The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. *J Bone Miner Res (2003)18:859-867.*
4. Grey A. et al., A role for interleukin-6 in parathyroid hormone-induced bone resorption *in vivo*. *Endocrinology (1999)140:4683-4690.*
5. Mayer J. et al., Comparison of biochemical markers of bone turnover in the ovariectomized Sprague-Dawley rat. Submitted (2002)
6. Qvist P. et al., Detection of collagen fragments generated by osteoclastic bone resorption in cultures of foetal mouse tibia; comparison to 45Ca detection. *J Bone Miner Res (2000)15;S465*
7. Seidlova-Wuttke D. et al., Pharmacology of Cimicifuga racemosa extract BNO 1055 in rats: bone, fat and uterus. *Maturitas (2003)44;Suppl1:S39-S50.*
8. Windahl SH. et al., Female estrogen receptor beta-/- mice are partially protected against age-related trabecular bone loss. *J Bone Miner Res (2001)16;1388-1398.*

Document Number: AC-06PL
Issue: 3
Date: 21 November 2008

EXP	GB	*Use By*	LOT	GB	*Batch code*
	DE	*Verwendbar bis*		DE	*Chargenbezeichnung*
	ES	*Fecha de caducidad*		ES	*Código de lote*
	IT	*Utilizzare entro*		IT	*Codice del lotto*
	FR	*Utiliser jusque*		FR	*Code du lot*
	NL	*Houdbaar tot*		NL	*Lot nummer*
	DK	*Holdbar til*		DK	*Lotnummer*
	CZ	*Použitelné do*		CZ	*Číslo šarže*
	SK	*Použiteľné do*		SK	*Číslo šarže*
	GR	*Ημερομηνία λήξης*		GR	*Αριθμός Παρτίδας*
	PT	*Prazo de validade*		PT	*Código do lote*
	HU	*Felhasználható*		HU	*Sarzsszám*
	SE	*Använd före*		SE	*Lot nummer*
	PL	*Użyć przed*		PL	*Kod partii*
REF	GB	*Catalogue number*		GB	*Manufacturer*
	DE	*Bestellnummer*		DE	*Hersteller*
	ES	*Número de catálogo*		ES	*Fabricante*
	IT	*Numero di catalogo*		IT	*Fabbricante*
	FR	*Référence du catalogue*		FR	*Fabricant*
	NL	*Catalogus nummer*		NL	*Fabrikant*
	DK	*Katalognummer*		DK	*Producent*
	CZ	*Katalogové číslo*		CZ	*Výrobce*
	SK	*Katalógové číslo*		SK	*Výrobca*
	GR	*Αριθμός καταλόγου*		GR	*Κατασκευαστής*
	PT	*Referência de catálogo*		PT	*Fabricante*
	HU	*Katalógusszám*		HU	*Gyártó*
	SE	*Katalognummer*		SE	*Tillverkare*
	PL	*Numer katalogowy*		PL	*Producent*
Σ	GB	*Contains sufficient for <n> tests*	IVD	GB	*In Vitro Diagnostic Medical Device*
	DE	*Inhalt ausreichend für <n> Prüfungen*		DE	*In-Vitro-Diagnostikum*
	ES	*Contenido suficiente para <n> ensayos*		ES	*Producto sanitario para diagnóstico in vitro*
	IT	*Contenuto sufficiente per "n" saggi*		IT	*Dispositivo medico-diagnostico in vitro*
	FR	*Contenu suffisant pour "n"tests*		FR	*Dispositif médical de diagnostic in vitro*
	NL	*Inhoud voldoende voor "n" testen*		NL	*Medisch hulpmiddel voor in-vitro diagnostiek*
	DK	*Indeholder tilstrækkeligt til "n" test*		DK	*Medicinsk udstyr til in vitro-diagnostik*
	CZ	*Lze použít pro <n> testů*		CZ	*In Vitro diagnostický zdravotnický prostředek*
	SK	*Obsah postačuje na <n> stanovení*		SK	*Zdravotnícka pomocka in vitro*
	GR	*Περιεχόμενο επαρκές για «ν» εξετάσεις*		GR	*In Vitro Διαγνωστικό Ιατροτεχνολογικό προϊόν*
	PT	*Conteúdo suficiente para "n" ensaios*		PT	*Dispositivo médico para diagnóstico in vitro*
	HU	*A doboz tartalma <n> vizsgálat elvégzéséhez elegendő*		HU	*In vitro diagnosztikum*
	SE	*Räcker till "n" antal tester*		SE	*Medicintekniska produkter för in vitro diagnostik*
	PL	*Wystarczy na wykonanie <n> testów*		PL	*Wyrób do diagnistyki In Vitro*
	GB	*Temperature limitation*		GB	*Consult Instructions for Use*
	DE	*Temperaturbegrenzung*		DE	*Gebrauchsanweisung beachten*
	ES	*Límite de temperatura*		ES	*Consulte las instrucciones de uso*
	IT	*Limiti di temperatura*		IT	*Consultare le istruzioni per l'uso*
	FR	*Limites de température*		FR	*Consulter les instructions d'utilisation*
	NL	*Temperatuurlimiet*		NL	*Raadpleeg de gebruiksaanwijzing*
	DK	*Temperaturbegrænsning*		DK	*Se brugsanvisning*
	CZ	*Teplotní rozmezí od do*		CZ	*Viz návod k použití*
	SK	*Teplotné rozmedzie od do*		SK	*Viď návod na pužitie*
	GR	*Περιορισμοί θερμοκρασίας*		GR	*Συμβουλευτείτε τις οδηγίες χρήσης*
	PT	*Limites de temperatura*		PT	*Consulte as instruções de utilização*
	HU	*Hőmérséklettartomány*		HU	*Nézze meg a Használati utasítást*
	SE	*Temperaturbegränsning*		SE	*Se handhavandebeskrivningen*
	PL	*Przestrzegać zakresu temperatury*		PL	*Sprawdź w instrukcji obsługi*

Immunodiagnostic Systems Ltd (IDS Ltd).

UK Immunodiagnostic Systems Ltd (IDS Ltd), 10 Didcot Way, Boldon Business Park, Boldon, Tyne & Wear, NE35 9PD
Tel: +44 (0) 191 519 0660 • Fax: +44 (0) 191 519 0760 • e-mail: info.uk@idsplc.com • www.idsplc.com
USA Immunodiagnostic Systems Inc (IDS Inc.), P.O. Box 17063, Fountain Hills, AZ 85269-7063
Tel: 480-836-7435 • Fax: 480-836-7437 • e-mail: info.us@idsplc.com • www.idsplc.com
Germany Immunodiagnostic Systems GmbH (IDS GmbH), Mainzer Landstrasse 49, 60329 Frankfurt am Main
Tel: +49 (0) 69 3085-5025 • Fax: +49 (0) 69 3085-5125 • e-mail: info.de@idsplc.com • www.idsplc.com
France Immunodiagnostic Systems EURL (IDS EURL), 55 rue Sainte Anne, 75002 PARIS
Tel: +33 (0)1 42 44 12 63 • Fax: +33 (0)1 42 44 40 76 • e-mail: info.fr@idsplc.com • www.idsplc.com
Scandinavia Immunodiagnostic Systems Nordic a/s (IDS Nordic a/s), Marielundvej 30, 2. Sal, 2730 Herlev, Denmark
Tel:+45 44 84 0091 • Fax:+45 44 84 0092 • email: info.nordic@idsplc.com • www.idsplc.com